Asselah T, et al. - Using this integrated analysis, the researchers intended to evaluate the efficacy of the once-daily combination of elbasvir 50 mg and grazoprevir 100 mg, with and without ribavirin in HCV genotype 4 (GT4)-infected members enrolled in phase 2/3 clinical programme with elbasvir/grazoprevir. They involved treatment-naïve and treatment-experienced participants 18 years of age or older with chronic HCV GT4 infection and baseline HCV RNA ≥10,000 IU/mL. Data reported that the regimens of 12 weeks of elbasvir/grazoprevir without ribavirin, and 16 weeks of elbasvir/grazoprevir plus ribavirin, were efficacious in HCV GT4-infected treatment-naïve and treatment-experienced participants respectively. In GT4-infected participants, baseline NS5A resistance-associated substitutions did not impact the efficacy of elbasvir/grazoprevir.